Novartis shares received a "Buy" rating from UBS AG, with a price target of 111 francs. Analyst Matthew Weston observed a slight sales surprise and a core EPS result that exceeded consensus estimates by 6 percent in his initial evaluation of the company's figures released on Tuesday morning.

Despite this positive assessment, Novartis shares declined by 3.2 percent to CHF 96.62 by 11:12 am in SIX SX trading. This drop suggests a potential growth opportunity of 14.88 percent compared to UBS's price target. The trading volume for Novartis shares recently reached 1,729,807, and the stock has seen an 18.1 percent increase in 2024.

Novartis is set to announce its Q3 2024 earnings and sales figures on October 29, 2024.